Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for license extension of insulin glargine / lixisenatide (Suliqua)

CHMP recommended a license extension for treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin, with or without SGLT-2 inhibitors.


European Medicines Agency